Efficacy and safety of moxidectin, synriam, synriam-praziquantel <em>versus</em> praziquantel against <em>Schistosoma haematobium</em> and <em>S.... (Publications)
analysis or three urine samples (S. haematobium trial) for urine filtration and one finger prick for malaria screening at baseline and follow-up. Participants were randomly assigned to either moxidectin, Synriam [...] hence an ancillary benefit is not expected when these drugs are used for treating onchocerciasis and malaria in co-endemic settings. Further studies are needed to corroborate our findings that moxidectin and
In vitro antiplasmodial activity and toxicity assessment of some plants from Nigerian ethnomedicine (Publications)
Plasmodium falciparum-resistant parasites to nearly all available antimalarial drugs pose a threat to malaria control and necessitates the need to continue the search for new effective and affordable drugs. [...] displayed antiplasmodial activity (IC(50) 2.3-16.9 microg/mL) with good selectivity (21-120) for malaria parasites. DISCUSSION AND CONCLUSION: The antiplasmodial activity of Terminalia catappa and Vitex
A worldwide map of <em>Plasmodium falciparum</em> K13-propeller polymorphisms (Publications)
BACKGROUND: Recent gains in reducing the global burden of malaria are threatened by the emergence of Plasmodium falciparum resistance to artemisinins. The discovery that mutations in portions of a P. [...] analyzed the K13-propeller sequence polymorphism in 14,037 samples collected in 59 countries in which malaria is endemic. Most of the samples (84.5%) were obtained from patients who were treated at sentinel
Current progress in the development and use of artemether for chemoprophylaxis of major human schistosome parasites (Publications)
schistosomiasis, a chronic and debilitating parasitic disease of the tropics, is ranked second after malaria in terms of public health importance. At present, there is no vaccine available, and chemotherapy [...] with artemether, the methyl ether of dihydroartemisinin, already widely used for the treatment of malaria. The present article reviews the literature that led to the development of artemether for chemop
The potential of artemether for the control of schistosomiasis (Publications)
Schistosomiasis continues to rank - following malaria - at the second position of the world's parasitic diseases in terms of the extent of endemic areas and the number of infected people. There is yet [...] Interestingly, derivatives of artemisinin, which are already effectively used in the treatment of malaria, also exhibit antischistosomal properties. Significant advances have been made with artemether, the
The three <em>Plasmodium falciparum </em>Aurora-related kinases display distinct temporal and spatial associations with mitotic structures in asexual... (Publications)
Aurora kinases are crucial regulators of mitotic cell cycle progression in eukaryotes. The protozoan malaria parasite Plasmodium falciparum replicates via schizogony, a specialised mode of cell division ch [...] throughout schizogony as well as in the non-dividing gametocyte stages, which are essential for malaria transmission. We demonstrate that all three PfARKs display distinct and highly specific and exclusive
Improving methods for analysing anti-malarial drug efficacy trials: molecular correction based on length-polymorphic markers <em>msp</em>-1,... (Publications)
BACKGROUND: Drug efficacy trials monitor the continued efficacy of front-line drugs against falciparum malaria. Over-estimates of efficacy result in a country retaining a failing drug as first-line treatment [...] modelling to simulate parasite dynamics and genetic signals that occur in patients enrolled in malaria drug clinical trials. We compared estimates of treatment failure obtained from a selection of proposed
Changes in metabolic phenotypes of <em>Plasmodium falciparum</em> <em>in vitro</em> cultures during gametocyte development (Publications)
s are the Plasmodium life stage that is solely responsible for malaria transmission. Despite their important role in perpetuating malaria, gametocyte differentiation and development is poorly understood
Two successful decades of Swiss collaborations to develop new anti-malarials (Publications)
Over the last two decades there has been a renaissance in the pipeline of new drugs targeting malaria, with the launch of new products that help save the lives of children throughout the world. In addition [...] Third, the emergence of product-development-partnerships, in this case led by the Medicines for Malaria Venture, based in Geneva, has helped to catalyze the development of new medicines and bring the community
Inhibitors of Plasmepsin II-potential antimalarial agents (Publications)
In order to overcome the problem of drug resistance in malaria, it appears wise to concentrate drug discovery efforts toward new structural classes and new mechanisms of action. We report our results,